1

CURRICULUM VITAE BRENT W. WESTON, M.D. October 25, 2013 Associate Professor of Pediatrics Division of Hematology – Oncology University of North Carolina at Chapel Hill EDUCATION: Fellowship and lecturer Pediatric Hematology/Oncology, Mott Children's Hospital, University of Michigan Medical Center, Ann Arbor, MI, 1988-1992. Postgraduate Pediatric internship and residency, University of North Carolina at Chapel Hill, NC, 1985-1988. Medical MD, Duke University School of Medicine, 1981-1985. Epidemiology and biostatistics research track, 1984-1985. Cancer Epidemiology summer internships, 1982 and 1983. Undergraduate BA, English, Duke University, Durham, NC Graduated magna cum laude, 1977-1981. New College, Oxford University, summer 1979 Senior thesis, Duke University, 1980-1981. EMPLOYMENT: Associate Professor of Pediatrics, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, 1999 - current Assistant Professor of Pediatrics, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, July, 1992-1999. LICENSURE AND CERTIFICATIONS: Board-certified in Pediatric Hematology/Oncology, Certificate #001054, 01/01/07-12/31/2016. Board-certified in Pediatric Hematology/Oncology, 1999-2006. Board-certified in General Pediatrics, 1999-2006.

2

Board-certified in Pediatric Hematology/Oncology, 1992-1999. Board-certified in General Pediatrics, 1989-1999. State of North Carolina Medical License, 1986-date, License #30578, registered annually. State of Michigan Medical License, 1988-1992.

3

HONORS AND AWARDS: Patients’ Choice Award, American Registry LLC, 2013 North Carolina Make-A-Wish Physician of the Year (Shooting Star Award), 2011. Consumers’ Research Council of America, Guide to America’s Top Oncologists, inclusion starting in 2009-date. Top-rating, MDX Medical Vitals.Com Physician Ratings, 2006-date. Consumers’ Research Council of America, Guide to America’s Top Pediatricians, inclusion starting in 2004. Consumers’ Research Council of America, Guide to America’s Top Physicians, inclusion starting in 2004. Veterans of Foreign Wars (VWF) Research Award, 2001. Council for Tobacco Research (CTR) Scholar Award, 1997-2000. University of North Carolina at Chapel Hill Junior Faculty Development Award, 1996-1997. Edward Curnen Book award for academic achievement, University of North Carolina at Chapel Hill, 1988. William Webb award for hematology/oncology patient care, University of North Carolina at Chapel Hill, 1987. Phi Beta Kappa, Duke University, 1980. Angier B. Duke Memorial Scholar, Duke University, 1977-1981. Early Identification Program, Duke University Medical School, 1978. BIBLIOGRAPHY: Selected publications in peer-reviewed journals:

1. Smitherman AB, Weston BW. Catheter-associated thrombosis in children: single institution experience and review of pediatric thromboembolic disease. J Infus Nurs., in press, 2013.

2. Weston BW, Monahan PE. Congenital deficiency of vitamin K-dependent clotting factors. Haemophilia , in press, 2013.

4

3. Chu Y, Liu Z, Weston B, Wang, B. Synthesis and evaluation of a fluorescent conjugate sLex-selective bisboronic acid for imaging applications. Bioorg Med Chem Lett, 23: 6307-6309, 2013. 4. Weston BW, Hayden MA, Roberts KG, Bowyer S, Hsu J, Fedoriw G, Rao KW, Mullighan CG. Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB–Positive Acute Lymphoblastic Leukemia. J Clin Oncol. 2013 Sep 1;31(25):e413-6. doi: 10.1200/JCO.2012.47.6770. Epub July, 2013. 5. Blatt J, Weston B, Gold S. Fatigue and Irritability as Markers of Thrombocytopenia in Childhood Idiopathic Thrombocytopenic Purpura. Pediatr Hematol Oncol 27: 65-67, 2010. 6. Taylor-Cousar JL, Zariwala MA, Burch LH, Pace RG, Drumm ML, Calloway H, Fan H, Weston BW, Wright FA, Knowles MR; Gene Modifier Study Group. Histo-blood group gene polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease severity. PloS ONE 4: e4270, 2009. 7. Weston BW, Monahan PE. Familial deficiency of vitamin K-dependent clotting factors. Haemophilia 14: 1209-1213, 2008. 8. Yang W, Fan H, Gao X, Gao S, Karnati V, Ni W, Hooks WB, Carson J, Weston B, and Wang

B. The first fluorescent diboronic acid sensor specific for hepatocellular carcinoma cells expressing sialyl Lewis X. Chem. & Biol., 11: 439-448, 2004. 9. Cakir B, Heiss G, Pankow JS, Salomaa V, Sharrett RA, Couper D, Bray M, Weston BW. Association of the Lewis genotype with cardiovascular risk factors and subclinical carotid atherosclerosis: the ARIC study. J. Int. Med., 255: 40-51, 2004. 10. Cakir B, Pankow JS, Salomaa V, Couper D, Morris TL, Brantley KR, Hiller KM, and Weston BW. Distribution of Lewis (FUT-3) genotype and allele frequencies in a bi-ethnic U.S. population: the ARIC study. Ann. Hematol., 81: 558-565, 2002. 11. Yang W, Gao S, Gao X, Karnati V, Ni W, Wang B, Hooks WB, Carson J, and Weston B. Diboronic acids as fluorescent probes for cells expressing sialyl Lewis x. Bioorgan & Med Chem Let, 12: 2175-2177, 2002. 12. Richardson MW, Funkhouser WK, Senior B, and Weston BW. Spindle cell lesions of the head and neck mimicking rhabdomyosarcoma in children. Pediatr. Hematol. Oncol., 19: 129-134, 2002. 13. Blatt, J, Weston, B, Belhorn, T, Hamrick, H, and Maia, D. Childhood non-Hodgkin's lymphoma presenting as hemophagocytic syndrome. Pediatr. Hematol. Oncol., 19: 45-49, 2002. 14. Weston, BW, Lin, JL, Muenzer, J, Cameron, HS, Arnold, RR, Seydewitz, HH, Mayatepek,E, Van Schaftingen, E, Veiga-Da-Cunha, M, Matern, D, and Chen, YT. Glucose-6-phosphatase mutation G188R confers an atypical glycogen storage disease type 1b phenotype. Pediatr. Res.,

5

48: 329-334, 2000. 15. Salomaa V, Pankow J, Heiss G, Cakir B, Eckfeldt JH, Ellison, C., Myers, R., Hiller KM, Brantley KR, Morris TL, and Weston BW. Genetic background of Lewis negative blood group phenotype and its association with atherosclerotic disease in the NHLBI family heart study. J. Int. Med., 247: 689-698, 2000. 16. Hiller, K.M., Mayben, J.P., Bendt, K.M., Manousos, G.A., Singer, K., Cameron, H.S., and Weston, B.W. Transfection of alpha(1,3)fucosyltransferase antisense sequences impairs the proliferative and tumorigenic ability of human colon carcinoma cells. Mol. Carcinog., 27: 280-288, 2000. 17. Weston BW, Hiller KM, Mayben JP, Manousos GA, Nelson CM, Klein MB, and Goodman JL. A cloned CD15s-negative variant of HL60 cells is deficient in expression of FUT7 and does not adhere to cytokine-stimulated endothelial cells. Eur. J. Haematol., 63: 42-49, 1999. 18. Weston, BW, Hiller, KM, Mayben, JP, Manousos, GA, Bendt, KM, Liu, R, and Cusack, JC, Jr. Expression of human alpha(1,3)fucosyltransferase antisense sequences inhibits selectin-mediated adhesion and liver metastasis of colon carcinoma cells. Cancer Res., 59: 2127-2135, 1999. 19. Goodman JL, Nelson CM, Klein MB, Hayes SF, and Weston BW. Leukocyte infection by the granulocytic ehrlichiosis agent is linked to expression of a selectin ligand. J. Clin. Invest., 103: 407-412, 1999. 20. Weston BW and Lauria M. Patient advocacy in the 1990s. N Engl J Med, 334: 543-544, 1996. 21. Cameron HS, Szczepaniak DA, and Weston BW. Expression of human chromosome 19p alpha(1,3)fucosyltransferase genes in normal tissues: alternative splicing, polyadenylation, and isoforms. J Biol Chem, 270: 20112-20122, 1995. 22. McCurley RS, Recinos A, Olsen, A, Gingrich, J, Szczepaniak DA, Cameron HS, Krauss R, and Weston BW. Physical maps of human alpha(1,3)fucosyltransferase genes FUT3-FUT6 on chromosomes 19p13.3 and 11q21. Genomics, 26: 142-146, 1995. 23. Mollicone R, Reguigne I, Kelly RJ, Fletcher A, Watt J, Chatfield S, Aziz A, Cameron HS, Weston BW, Lowe JB, and Oriol R. Molecular basis for Lewis alpha(1,3/1,4) fucosyltransferase gene deficiency (FUT3) found in Lewis-negative Indonesian Pedigrees. J Biol Chem, 269: 20987-20994, 1994. 24. Mollicone R, Reguigne I, Fletcher A, Aziz A, Rustam M, Weston BW, Kelly RJ, Lowe JB, and Oriol R. Molecular basis for plasma alpha(1,3) fucosyltransferase gene deficiency (FUT6). J Biol Chem, 269: 12662-12671, 1994. 25. Weston BW, Smith PL, Kelly RJ, Lowe JB. Molecular cloning of a fourth member of a

6

human alpha(1,3)fucosyltransferase gene family: multiple homologous sequences that determine expression of the Lewis x, sialyl Lewis x, and difucosyl sialyl Lewis x epitopes. J Biol Chem 267: 24575-24584, 1992. 26. Wong CH, Dumas DP, Ichikawa Y, Koseki K, Danishefsky SJ, Weston BW, Lowe JB. Specificity, inhibition, and synthetic utility of a recombinant human alpha(1,3)fucosyltransferase. J Am Chem Soc 114: 7321-7322, 1992. 27. Ball GE, O'Neill R, Schultz JE, Lowe JB, Weston BW, Nagy JO, Brown EG, Hobbs C, Bednarski MD. Synthesis and structural analysis using 2-D NMR of sialyl Lewis x (SLex) and Lewis x (Lex) oligosaccharides: Ligands related to E-selectin [Elam-1] binding. J Am Chem Soc 114: 5449-5451, 1992 28. Weston BW, Nair RP, Larsen RD, Lowe JB. Isolation of a novel human alpha(1,3)fucosyltransferase gene and molecular comparison to the human Lewis blood group alpha(1,3/1,4)fucosyltransferase gene. Syntenic, homologous, non-allelic genes encoding enzymes with distinct acceptor substrate specificities. J Biol Chem 267: 4152-4160, 1992. 29. Ross CW, Schnitzer B, Weston BW, Hanson CA. Chronic active Epstein-Barr virus infection and virus-associated hemophagocytic syndrome. Arch Pathol Lab Med 115: 470-474, 1991. 30. Weston BW, Axtell RA, Todd RF, Vincent M, Balazovich KJ, Suchard SS, Boxer LA. Clinical and biologic effects of granulocyte-colony stimulating factor in the treatment of myelokathexis. J Pediatr 118: 229-234, 1991. 31. Weston BW, Todd RF, Axtell RA, Balazovich KJ, Stewart J, Locey BJ, Mayo-Bond L, Loos P, Hutchinson R, Boxer LA. Severe congenital neutropenia: clinical effects and neutrophil function during treatment with granulocyte-colony stimulating factor. J Lab Clin Med 117: 282-290, 1991. 32. Weston BW, Grufferman S, MacMillan JP, Cohen HJ. Effects of socioeconomic and clinical factors on survival in multiple myeloma. J Clin Oncol 4: 1977-1989, 1987. 33. Weston BW, Grufferman S, Kostyu D, Burton CS, Grant J. Familial aggregation of melanoma, basal cell carcinoma, and gastric adenocarcinoma. Cancer 47: 2230-2234, 1986. A list of manuscripts in progress can be obtained by request. Selected Abstracts (most published; poster unless presentation noted): 1. Smitherman AB, Alexander T, Connelly M, Weston BW and Steiner MJ. The incidence of catheter-associated venous thromboembolism in non-critically ill children. Pediatric Academic Societies Annual Meeting, Washington, DC, May 2013. EPAS 2013: 750555. (presentation)

7

2. Buckner T, Nielsen B, Weston B, Monahan P. Combined T- and B-cell immunosuppressive therapy for immune tolerance induction in 4 patients with inhibitors: 2 with severe factor VIII deficiency and 2 with severe factor IX deficiency. (presentation); Abstracts of the XXIV World Congress of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11(s2): 668. 3. Hayden, M, Bowyer S, Hsu J, Weston B, Gold, Rao K. Response to Tyrosine Kinase Inhibitor in a High Risk Pediatric ALL Patient with a Newly Characterized PDGFRB Rearrangement. Poster and presentation at: 42nd Biennial American Cytogenetics Conference, San Antonio, TX, April 20th, 2012. 4. Coulter DW, Gold SH, Weston B, Davis I, and Blatt J. A phase I study of temsirolimus and valproic acid for refractory solid tumors in children. ASCO abstract #73397, for ASCO Annual Meeting (June 3-7, 2011); J Clin Oncol, 2011. 5. Lee K, Berg JS, Monahan PE, Weston, BW, Key NS, Nielsen BI, Grimsley AL, Wright SS, and Evans JP. A novel rare duplication identified in F8 gene from a large Native American kindred with severe hemophilia A. Presented at American College of Medical Genetics (ACMG), March 2010, Am J Med Genetics, 2010. 6. Patel S, Moats-Staats BM, Weston BW, and Calikoglu AS. Insulin dependent diabetes mellitus in two patients with Shwachman-Diamond-like syndrome. E-PAS 2007: 617915.10, (presented May 7, 2007) 7. Taylor JL, M Zariwala, L Burch, RG Pace, A Handler, MW Konstan, MD Schluchter, DA Schwartz, JR Yankaskas, ML Drumm, FA Wright, H Fan, BW Weston and MR Knowles. Polymorphisms in the ABH Genes as Gene Modifiers in Cystic Fibrosis. Pediatric Pulmonolology 41: A200, 2006. 8. Fan H, Zheng B, and Weston B. Hereditary neutrophilia: benign proliferation of neutrophils associated with a mutation in the G-CSF receptor. (summary in Leukemia Research, 31: 11, 2007); presentation, 3rd International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes, October 28, 2005. 9. Richardson, MW, Hooks, WB, Faires, PM, Monia, BP, Johnston, JF, and Weston, BW. Inhibition of selectin ligand expression on metastatic tumor cells with antisense oligonucleotides. J. Pediatr. Hematol. Oncol. 23: A37, 2001. 10. Hooks, WB, Brier, SE, Monia, BP, Johnston, JF, and Weston, BW. Inhibition of hepatocellular carcinoma proliferation with FUT6 antisense oligonucleotides. J. Pediatr. Hematol. Oncol., 23: A21, 2001. 11. Larson, J, Klein, M, Nelson, C, Weston, B, and Goodman, JL. Human granulocytic ehrlichiosis interactions with target cells: identification of additional susceptible cell lines and further dissection of the role of cellular adhesions. CDC Emerging Infection Meeting, ICEID, Abstract P-9.26: 103, 1998. (presentation)

8

12. Goodman, JL, Nelson, CM, Klein, MB, and Weston, BW. Leukocyte sialylated Lewisx is a critical cell surface molecule for infection by the agent of human granulocytic ehrlichiosis. Am. J. Trop. Med. Hyg., 57: 245, 1997. (presentation) 13. Lin, JL, Muenzer, J, Weston, BW, Chen, YT. New mutations of glycogen storage disease type 1A and an unusual type 1B phenotype in a patient. Am. J. Human Genet., 59: A203, 1996. 14. Bendt, KM, Senger KH, Weston, BW. The human Lewis blood group alpha(1,3/1,4) fucosyltransferase promoter. Pediatric Research, 39: 152A, 1996. 15. Cameron, HS, Szczepaniak DA, Weston, BW. Differential expression of human chromosome 19p alpha(1,3)FUT transcripts: alternative splicing and polyadenylation of FUT3 and FUT6. Blood, 84: 600a, 1994. 16. McCurley RS, Cameron HS, Szczepaniak DA, Recinos A, Krauss R, Evans G, Weissman B, Weston, BW. Physical maps of the human alpha(1,3)fucosyltransferase loci. Pediatric Research, 35: 165A, 1994. 17. Cameron HS, Szczepaniak DA, McCurley RS, Weston, BW. Expression of alpha(1,3)fucosyltransferase genes in human kidney. Pediatric Research 35: 159A, 1994. 18. O'Neill RA, Ball G, de Vries T, Schultz JE, Nagy JO, Hobbs C, Lowe B, Weston BW, van den Eijnden DH, Bednarski M. Synthesis, purification, and analysis by 2-D NMR of sialyl-Lewis X tetrasaccharide and the related Lewis X-O-allyl glycoside. J Cell Biochem 16D: 157, 1992. 19. Weston BW, Kelly RW, Lowe JB. Defining a glycosyltransferase gene family: Cloning and expression of a gene encoding a GDP-fucose:N-acetylglucosaminide 3-alpha-L-fucosyltransferase homologous to but distinct from known human alpha(1,3)fucosyltransferases. J Cell Biochem 16D: 150, 1992. 20. Lowe JB, Weston BW, Kelly RW, Larsen RD, Ernst LK, Nair RP. Structural and functional diversity in human fucosyltransferase genes. Glycoconjugate J 8: 145, 1991. 21. Weston BW, Locey B, Todd RF, Hutchinson RJ, Boxer LA. Treatment of congenital neutropenia with rG-CSF. Pediatr Research 25: 158A, 1989. (presentation) 22. Weston BW, Grufferman S, MacMillan J, Cohen HJ. Effects of socioeconomic factors on survival in multiple myeloma. Clin Research 34: 387A, 1986. (presentation) 23. Weston BW, MacMillan JP, Cohen HJ, Grufferman S. Effects of socioeconomic and clinical factors on survival in multiple myeloma. Proc ASCO 5: 214, 1986. (presentation) Other articles, letters, and reviews:

9

1. Weston, BW. Immune Interferon: Properties and Clinical Applications. Annals of Pharmacotherapy, 36: 1655, 2002. (book review) 2. Weston, BW. Leukemias. in The Manual of Clinical Problems in Pediatrics, Kenneth B. Roberts, ed., Lippincott Williams & Wilkins: 2001. (mini-review chapter) 3. Weston, BW. Wiskott-Aldrich Syndrome (WAS). in Essence of Office Pediatrics, James A. Stockman, and Jacob A. Lohr eds., Saunders: 2001. (mini-review chapter) 4. Weston, BW and Lauria M. Patient Advocacy in the 1990s. N Engl J Med, 335: 137, 1996. (author replies) 5. Weston, BW and MacMillan JP. Ceftazidime vs. placebo in respiratory exacerbations of cystic fibrosis. J. Pediatr., 113: 618, 1988. (letter) 6. Weston, BW. In time. NC Med J., 48: 608, 1987. (poem) Presentations Content is mostly unpublished data, but see also abstract section. I am invited speaker unless otherwise noted. Medical school teaching is not included here. 1. Weston B and Smitherman, A. Catheter-associated thromboses in pediatrics. Presentation at the INS annual meeting, Charlotte, NC, May 22, 2013. 2. Hayden, M, Bowyer S, Weston B, Rao K. Response to Tyrosine Kinase Inhibitor in a High Risk Pediatric ALL Patient with a Newly Characterized PDGFRB Rearrangement. Platform presentation: 2012 Annual Research Symposium, Department of Pathology and Laboratory Medicine, UNC-CH, September 14, 2012. 3. Weston B. UNC School of Dentistry, Maternal and Child Health Seminar Series: “Clinical Management of Hemophilia,” March 9, 2012. 4. Weston B. UNC School of Nursing, CPON review course: “Neutrophil Disorders in Children,” November 30, 2011. 5. Weston B. UNC School of Nursing, CPON review course: “Pediatric Thrombosis: UNC Experience,” November 16, 2011. 6. Weston, B. and Smitherman, A. UNC Pediatric Grand Rounds: “Catheter-associated DVTs,” October 6, 2011. 7. Weston, B. Dept. of Pediatric Dentistry, UNC-CH: “Neutrophil Disorders in Pediatric Patients,” 1 hour, September 29, 2011.

10

8. Weston, B. Thrombosis in Pediatric Patients, Pediatric Hematology Conference Series, 1 hour, March 10, 2011. 9. Weston , B. Platelet Disorders, Pediatric Hematology Conference Series, 1 hour, October 7, 2010. 10. Weston, B. Cape Fear Valley Health System, “Pediatric Coagulation Update.” 1 hr, March 12, 2010. 11. Weston, B. UNC Pediatric Board Review, "Pediatric Solid Tumors." 1 hour, May 11, 2009. 12. Weston, B. UNC Pediatric Hem/Onc Conference: “Neutrophil Disorders: What You Need to Know.” 1 hour, January 28, 2009. 13. Weston, B. Dept. of Pediatric Dentistry, MCHS series, UNC-CH: "Chronic neutrophil disorders," 1 hour, November 7, 2008. 14. Weston, B. "Children and Blood Clots." Seminar on Blood Clots and Blood Clotting Disorders, invited speaker, UNC-CH and NATT co-sponsors, March 1, 2008. 15. Weston, B and DeCamp, L. UNC Department of Pediatrics Grand Rounds: Pulmonary Embolism in Older Children and Adolescents. One hour. December 20th, 2007. 16. Weston, BW, UNC GI-SPORE, two posters and three presentations, materials for project 5, available on request. Three annual national meetings and site visits. See aims in grants section. 2004-2007. 17. Weston, B. Dept. of Pediatric Dentistry, UNC-CH: "Chronic neutrophil disorders in children," 1 hour, October 28, 2005. 18. Weston, B. Panel Member, UNC Medical School, for all interested medical students, “Careers in Hematology/Oncology,” 1 hour sessions, invited by Dr. Georgette Dent, 2003-2007. 19. Xingming Gao, Haiying Fan, Wenqian Yang, Shouhai Gao, Vishnu V. R. Karnati, Weijuan Ni, Borden Hooks, John Carson, Brent Weston, and Binghe Wang. “Development of Boronic Acid-based Fluorescent Sensors for Cell Surface Carbohydrates.” 2nd Annual Georgia State Biotech Symposium, May 24—25, 2004, Atlanta, GA. 20. Weston, BW, and Wang, B. “Progress in the Development and Testing of 2nd Generation Boronic Acid-based Fluorescent Sensors” NCI site visit, Georgia State Dept of Chemistry, Atlanta, Weston lab presentations for 5 hours, April 7-8, 2004. 21. Weston, BW. Combined NCI site visit, UNC/NCSU, including seminars: “Fucosylated Carbohydrates as Onco-Developmental Antigens” and "Translational Opportunities using Carbohydrate Markers." 3 hours, April 15, 2003.

11

22. Wang B and Weston BW. “Boronic acid receptors specific for carcinoma cells expressing sialyl Lewis x.” NCI Principal Investigators Meeting, February 17, 2003, San Diego, CA. 23. Weston, B. UNC Pediatric Interest Group, first and second year medical students, “Careers in Pediatric Hematology/Oncology, 1 hour, October 29, 2002. 24. Weston, B. Dept. of Pediatric Dentistry, UNC-CH: "Neutropenias and diseases of neutrophil function," 1 hour, September 20, 2002. 25. Yang W, Gao S, Gao X, Karnati V, Ni W, Hooks WB, Carson J, Weston B, and Wang B. Fluorescent sensors for cells expressing sialyl Lewis x. Presented at the 3rd Innovative Molecular Analysis Technology Symposium, Washington, D.C., July 8-10, 2002. 26. Yang W, Gao S, Gao X, Karnati V, Ni W, Hooks WB, Carson J, Weston B, and Wang B. Diboronic acids as fluorescent sensors for cells expressing sialyl Lewis x. Presented at the 28th National Medicinal Chemistry Symposium, San Diego, CA, June, 2002. 27. Departmental research poster, (with Matt Richardson), UNC Department of Pediatrics, Thomas F. Boat Evening of Scholarship, May 28, 2002. 28. Research seminar: "Alpha (1,3) fucosyltransferase Antisense Sequences Impair the Proliferative Ability of Human Carcinoma Cells," invited by UNC Gene Therapy Center, 1 hour; April 16, 2002. 29. Departmental research poster, (with Matt Richardson), UNC Department of Pediatrics, Thomas F. Boat Evening of Scholarship, March 27, 2001. 30. Weston, B. Pediatric Grand Rounds, Moses Cone Hospital, Greensboro, NC: "Neutrophil Disorders;" 1 hour; April 18, 2001. 31. Research seminar: "HPLC, FACE, and CE techniques for carbohydrate analysis," with Beth Miller, Glyko, Inc; 1 hour; March 22, 2001. 32. Research & development meetings with incuVest representatives and collaborators, "Inhibition of selectin ligands in colon cancer," with Binghe Wang, 3 hours, October 18, 2000. 33. Weston, B. UNC Hospitals Dept. of Microbiology lecture series, "Leukocyte Adhesion Deficiency," with Cindy Bristow, 1 hour, September 27, 2000. 34. Weston, B. Chapel Hill Pediatrics CME seminars, "Evaluation of bleeding disorders in children," invited lecturer, with Paul Monahan, 90 minutes, November 17, 1999. 35. Weston B. UNC Dental School: "Chronic neutropenias: an update," 1 hour, November 5, 1999. 36. Weston, B. UNC Department of Pediatrics Grand Rounds, "Neutropenia in a Previously

12

Healthy Child," 1 hour, with Fred Henderson and Leonard Stein, March 25, 1999. 37. Weston, B. UNC Pediatric Gastroenterology Journal Club, "Congenital Thrombotic Disorders," invited speaker, 1 hour, November 24, 1998. 38. Weston, B. Rockingham County Medical Society Meeting, CME lecture, invited by Greensboro AHEC, "Pediatric Cancer Update," 3 hours, September 17, 1998. 39. American Council of Life Insurance (ACLI) 23rd Annual Meeting, Medical Section, Asheville, NC, invited lecturer: "Clinical Signs of Cancer in Pediatrics & Adult Survivors of Pediatric Cancer," June 30, 1998. 40. G Allen, BW Weston, JP Mayben, KM Hiller, JL Goodman. A cloned CD15s-negative variant of human myeloid cells is deficient in expression of Fuc-TVII and does not adhere to cytokine-stimulated endothelial cells, poster, UNC Department of Pediatrics, Thomas F. Boat Evening of Scholarship, March 31, 1998. 41. Weston, B Morehead Memorial Hospital, Eden, NC, Grand Rounds: "Overview of Pediatric Cancers," 1 hour, February 18, 1998. 42. Weston, B. Wake Medical Center, Raleigh, Pediatric Grand Rounds: "Neonatal Anemia," 1 hour, May 21, 1997. 43. Weston, B. Johnson Scholar Program, invited lecturer, "Careers in Academic Medicine", 1 hour, February 25, 1997. 44. Weston, B. Duke/UNC Hematology-Oncology Joint Conference: "Expression of Fucosyltransferases in Human Epithelial Cells", 1 hour, February 20, 1997. 45. Weston, B. UNC School of Dentistry, Dental Research Center, invited lecture: "Neutrophil Dysfunction," 2 hours, February 6, 1997. 46. Weston, B. Columbia, S.C. Public Schools, invited speaker: "Careers in Biological Sciences and Medicine," 3 hours, November 13-14, 1996. 47. Weston, B. UNC Department of Physiology Seminars: "Regulation of Selectin Ligands in Colon Carcinoma," 1 hour, October 28, 1996. 48. Weston, B. UNC School of Nursing, Advanced Oncology Nursing Practice Series, invited speaker: "Leukemias and Related Disorders," 1.5 hours, October 15, 1996. 49. Weston, B. UNC Clinical Seminars in Pediatric Dentistry: "Cyclic Neutropenia", 1 hour, October 4, 1996. 50. Weston B. UNC Department of Pediatrics Faculty Research Seminar: "Highlights of Research in the Hematology/Oncology Division", with Joseph Wiley, MD, 1 hour, October 1,

13

1996. 51. Weston, B. N.I.E.H.S. Chief J. Carl Barrett, invited seminar, "Expression of fucosylated glycans and alpha(1,3)fucosyltransferases in human adenocarcinoma," 1 hour, September 13, 1996. 52. Weston, B. UNC-CH Curriculum in Genetics and Molecular Biology: "Differential Expression of human alpha(1,3)fucosyltransferase genes", 1 hour, invited by Susan Lord, Director. February 2, 1996. 53. Weston, B. UNC Department of Pediatrics Grand Rounds: "Neutrophil Disorders in Childhood", 1 hour, September 14, 1995. 54. Szczepaniak DA, Cameron HS, Weston, BW. "Post-transcriptional regulation of alpha(1,3)fucosyltransferase gene (FUT6): alternative splicing, polyadenylation, and isoform expression," poster, UNC Department of Pediatrics, Thomas F. Boat Evening of Scholarship, April 5, 1995. 55. Weston, B. UNC Department of Pathology, Seminars in Pathology: "Differential expression of three human fucosyltransferase genes: synthesis of selectin ligands", 1 hour, March 28, 1995. 56. Weston, B. UNC Department of Pediatrics Subspecialty Conference: "Neutropenic Disorders in Childhood", 1 hour, March 9, 1995. 57. AHEC continuing medical education series: "Pediatric Hematology/Oncology Update", Brent Weston, M.D. (pediatric malignancies and white blood cell disorders) and Paul Monahan, M.D. (red blood cell and coagulation disorders). 5 hours total. Fayetteville Area Health Education Center (FAHEC), March 1, 1995. 58. Weston, B. Dental research center, oral biology seminar series: "White blood cell disorders", 1 hour, September 29, 1994. 59. Weston, B. Wake Medical Center, Raleigh, Pediatric Grand Rounds: "WBC disorders," 1 hour, August 17, 1994. 60. Szczepaniak DA, Cameron HS, McCurley RS, Weston, BW. "Expression of alpha(1,3)fucosyltransferase genes in human tissues," poster, UNC Department of Pediatrics, Thomas F. Boat Evening of Scholarship, April 6, 1994. 61. Weston, B. Pediatric Faculty Research Seminar: "Carbohydrate-mediated cell adhesion: role of alpha(1,3)fucosyltransferase genes," 1 hour, February 1, 1994. 62. Weston, B. Moses H. Cone Memorial Hospital Pediatric Grand Rounds: "Immune thrombocytopenia purpura," 1 hour, June 30, 1993.

14

63. Weston, B. Rutherfordton Hospital Medical Staff Conference, "Infectious complications in oncology," 1 hour, February 12, 1993. 64. Weston, B. "Carbohydrates as oncodevelopmental antigens," 1 hour, University of Michigan Medical Center, Department of Pediatrics, Research Seminar, February 12, 1992. TEACHING RECORD: Current teaching responsibilities include bedside teaching of medical students, residents, and fellows in mostly inpatient settings, and didactic lectures for housestaff (at least 2 lectures per resident group and 4 lectures per fellow group). 1992-date. I actively participate in the recruitment of residency and fellowship applicants (at least 8 interviews per year for each). 1992-date. Clinical and scientific seminars and lectures are ongoing activities (see bibliography section). 1992-date. I also continue to teach in continuing medical education seminars. 1992-date. Special areas of teaching interest now include coagulation defects (especially thrombosis and thrombophilia). This includes patient education through the National Alliance for Thrombosis and Thrombophilia (NATT). 2007-date. Training of research fellows and students in my laboratory included daily review of data, design of experiments, and weekly laboratory meetings. The following research trainees, who now have advanced degrees, were under my direct supervision from1992-2007: H. Scott Cameron, MD (10/92-7/95) R. Skyler McCurley, MD (6/93-7/94) Dorota Szczepaniak, MD (7/93-7/95) Kate Senger, PhD (7/94-8/96) Katharine Bend, MS (8/95-1/97) George Manousos, MD/PhD (1/96-4/97) John Mayben, MS (2/97-2/98) Tammy Morris, MD (6/96-6/98) Ana-Maria Temple, MD (7/98-10/98 Kelly Brantley, MPH (8/97-12/98) Sonia Pratap, MPH (8/98-5/99) Kara Hiller, MS, MD (3/97-7/99) W. Borden Hooks, MD (7/99-7/01) Penny Faires, MD (5/00-5/01) Matthew Richardson, MD (7/00-7/02) Sarah Brier, MD (5/00-5/03) Heather Garren, MS (1/01-5/03) John Martin, MD (6/03-5/05)

15

Amy Jost, MD (5/04-8/04) Veena Rao, MS (5/02-5/06) Haiying Fan, MD (3/02-10/07) I taught a major part of the hematology/oncology pathophysiology course for 2nd year medical students. This included responsibility for 2-3 lectures (White Blood Cells, Acute Leukemias, Pediatric Tumors, Pediatric Hematology) and sometimes labs related to lectures. Fall 1993-2007. Faculty preceptor, Pediatric Interest Group, Subspecialty Shadowing, 2007-date. Faculty member of the Curriculum in Genetics and Molecular Biology; teaching responsibilities at the graduate student level, including prelim. exam design and grading. 1996-2007. Carolina summer reading program, small group leader, 2005-2007. Introduction to Clinical Medicine (ICM) course, Pediatrics, 2-3 three hour sessions each year, 2nd year medical students, 2004-2011. Guest lecturer, 3rd year medical students on general pediatrics rotation, January 2002-2004. Bimonthly one hour clinical lectures: two common hematology cases, for 3rd year medical students on the general pediatrics rotation (about 6 lectures per year). January 1994-November 2001. PhD Committee of Banu Cakir, a graduate student working in the Cardiovascular Epidemiology Program in the UNC School of Public Health, 1999-2000. Advisor for Victoria Lee and Carol Albright, students in the UNC MD-PhD Program, 1997-1999. Laboratory research preceptor in the Cancer Education Program, Summer, 1996, and Summer, 1998. PhD Committee of Henry Liu, a graduate student in the Oral Biology Program in the UNC School of Dentistry, 1996-1998. Participated in the development of a course in the PhD curriculum in Oral Biology entitled "The Molecular and Cellular Pathogenesis of Inflammatory Diseases." This course was part of a competitive initiative to establish a Comprehensive Center for Inflammatory Disorders at UNC. Fall 1996. Nominated for a UNC Distinguished Teaching Award for Post-Baccalaureate Instruction in November, 1996. I regularly wrote questions for the American Board of Pediatrics certifying examinations. 1990-

16

1996. GRANTS & SUPPORT: (enGrant search 2000-2011 showed 2.1 million dollars total, not including training grants). Note: these listings do not include open label drug studies that I am CO-PI on for hemophilia (n=4 from 2008-2012) or COG studies (about 50 open trials at any one time). 1. Grant #UO1DD00292 Moll (PI). 07/15/07-06/30/12. Centers for Disease Control and Prevention Weston (CO-PI) Block $200,000 first year direct costs; 5% effort for Weston until 2011 "Thrombosis and Hemostasis Centers Research and Prevention Network." 2. Grant #CA123329 Wang (PI) 9/20/06-9/19/2010 Weston (CO-PI) National Cancer Institute $50,000 first yr direct costs; total costs $547,500 over four years for our sub-contract. "MRI contrast agents targeting carbohydrate biomarkers." The specific aims of the application involved design and synthesis of new MRI contrast agents. 10% salary. *NOTE: I closed my lab on October 31, 2007 and thus withdrew from this grant after year 1. 3. Grant #CA106991: UNC SPORE in Gastrointestinal Cancer National Cancer Institute 04/01/04-03/31/09* Tepper, PI. Year 1 direct costs: $164,619; total direct costs: $870,818 Weston, PI (30% effort) on Project 5: "Determination of the Role of Fucosyltransferases in Colorectal Cancer Initiation and Progression." The goals were to identify FUT3 and FUT6 SNPs associated with polyp and CRC development; examine potential interactions with use of non-steroidal anti-inflammatory drugs and other clinical variables; examine FUT transcript levels in polyps and CRC lesions; and to combine FUT antisense oligodeoxynucleotides with NSAIDs in experimental therapy. *NOTE: despite progress on all aims, the project was cut in April 2007 (end of year 3) due to concerns about limited clinical applicability; documentation is available by request. 4. Subcontract with Cystic Fibrosis Center, UNC/Duke, subcontract: "FUT3 genotyping in cystic fibrosis patient subgroups." $28,904. Administered through LCCC. One year, 2006-2007. 5. Patent: Co-inventor, "Fluorescent Sensor Compounds for Detecting Saccharides," United States Patent #6916660, with Binghe Wang and Wenqian Yang, patent published July 12, 2005. 6. NCI Contract, UNC sub-contract, #2001-1601-01: "Boronic Acid-Based Sensors for Cell Surface Carbohydrates" in response to BAA N01-CO-17016-32, with Dr. Binghe Wang, NC State University, Dept. of Chemistry. March 1, 2002- February 28, 2005, $119,773 per year, total $359,199 (direct and indirect). 7. UNC Office of Undergraduate Research, Summer Undergraduate Research Fellowship Award, Mentor for Veena Rao, $3000, no salary. April 1, 2004.

17

8. Grant: Co-investigator/subcontractor 7/1/2000-6/30/2004 Weston, 10% salary. NCI: R21/R33 Total costs: $299,562 PAR-99-100: Innovative Technologies for Molecular Analysis of Cancer. PI: Binghe Wang, NC State University, Dept. of Chemistry "Fluorescent Tags Targeted on Cell Surface Carbohydrates" 9. Patent: Inventor, "Antisense Human Fucosyltransferase Sequences and Methods of Use Thereof," United States Patent #6350868, published February 26, 2002. 10. Research Award, Auxiliary to the Veterans of Foreign Wars 10/6/2001 "Novel Treatment Approaches for Advanced Colon Cancer, PI. Total award: $12,000 11. Grant: National Cancer Institute 1RO1 CA 84539-01 (Weston, PI) 40% salary. 04/01/2000-03/31/2005 Total costs: $771,658 (direct and indirect). "Experimental therapy of colon cancer with antisense FUTS" 12. Research mentor/CO-PI (7/1/2000-6/60/2002; no salary) with Matthew Richardson, fellow and recipient. Total award: $55,000. "Michael Hoefflin Research Fellow of the National Childhood Cancer Foundation" 13. Research Preceptor, NIH Short Term Research Training grant (STRT), May 28 - August 16, 2002, with W. Borden Hooks, MSII, $3,592 student stipend. 14. Grant: University Research Council, UNC-CH, Inhibition of FUT3/FUT6 with chimeric antisense oligonucleotides (PI), $4,000, 11/99-11/00. 15. Grant: Medical Faculty Research, UNC-CH, Inhibition of colon carcinoma cell adhesion and proliferation with morpholino oligonucleotides (PI), $4,000, 11/99-11/00. 16. Consultant: NIH (NIAID) #1RO1AI40952-01: Cellular and Molecular Pathogenesis of Human Granulocytic Ehrlichiosis (supplies, no salary), 04/01/97-03/01/2002. 17. CTR (Council for Tobacco Research) Scholar Award, Role of Selectin Ligands in Adenocarcinoma Metastasis, $150,000, 07/01/97-06/30/2000. Weston, PI. 18. Co-investigator (no salary, Weston on K08), Biosynthesis of tracheal mucous glycoproteins. Pi Wan Cheng, PI, 2/95-1/2000. 19. Subcontract: Atherosclerosis Risk in Communities (ARIC) Sub-Study Proposal, 1997-1999: The Association of Lewis Genotypes with Different Manifestations of Atherosclerosis and Atherosclerosis Risk Factors; $29,200. Co-investigator. 20. Grant: NCI Clinical Investigator Award (K08, CA01758, PI, 75% effort), Functions of

18

human (1,3)fucosyltransferase gene family, $361,017, 8/93-7/98. 21. Research Preceptor: Cancer Education Program Assistanceship (sponsor), $3000, 7/98-10/98. 22. Junior Faculty Development Award, UNC: Functional analysis of the FUT3 promoter region, $3,000, Weston PI. 1/1/96-12/31/96. 23. Research mentor: Howard Holderness Medical Fellowship (Weston, sponsor), $5,000, four of these, 1993-1997. 24. Research Preceptor: American Society of Hematology Summer Research Award (sponsor), $1200, 5/97-8/97. 25. Research Preceptor: Cancer Education Program Assistanceship (sponsor), $2100, 5/97-8/97. 26. Grant: University Research Council UNC-CH, Expression of alpha(1,3)fucosyltransferase genes in metastatic neuroblastoma (PI), $3,000, 5/94-6/95. 27. Support: from the UNC Center for Thrombosis and Hemostasis, $10,000 start-up, 2/94-8/94. 28. Support: from the Lineberger Comprehensive Cancer Center, $20,000 start-up, 1/93-1/94. 29. Research Preceptor: Haley Scholarship for Undergraduate Summer Research (sponsor), $1000 per summer, 1993, 1995, 1997, 1998, 2000, 2001. 30. Research Preceptor: Scott Neil Schwirck Fellowship (sponsor), $1,500, 1993. 31. Research Mentor: Howard Hughes Medical Student Fellowship (sponsor), $20,000, 7/93-6/94. 32. Grant: National Research Service Award, GM14279, (Weston and Lowe, CO-PIs), $60,000, 1/91-1/93. Pending Support: available by request. PROFESSIONAL SERVICE: Clinical responsibilities (currently about 90% effort). Most of the patients I see are entered into clinical trials or national registries; for oncology, this is through COG (about 50 open trials at any one time); for hemophilia and thrombosis, through various registries, including UNC listing PEDTHROMBO. For pediatric thrombosis patients, we are currently organizing a phase I trial of Xarelto (rivaroxban) with Bayer Pharmaceuticals, with the support of the CTRC.

19

For chronic neutrophil disorder patients, some recent service work includes enrollment of all CGD patients on the COMPASS program for interferon gamma, and establishment of the UNC registry PEDNEUTRO. Pediatric Hematology Consult Attending, a separate service, 5-8 weeks per year. 2009-date. This is Mon-Fri 8 AM – 4 PM in addition to inpatient and outpatient clinical responsibilities. Inpatient Attending Physician, Pediatric Hematology/Oncology Service, 12 weeks per year, plus several weekends/holidays per year. Coverage often includes 2-3 pediatric bone marrow transplant patients. All outpatient calls on nights and weekends come to the attending and/or fellow. 2007-date. Outpatient Attending Physician, Pediatric Hematology/Oncology Clinics, 10 half-days per week. In addition to general hematology and oncology patients, I am currently following about 100 patients with chronic neutrophil disorders and 100 patients with thrombosis and/or thrombophilia. We now have a long clinic day rotation as well, where one of us stays until the last patient is discharged; this occurs every 10 days. 2007-date. Clinical preceptor for NP student in N828: Advance Field Practicum in Community-Oriented Patient Care, January-April 2009. Outpatient Attending, Comprehensive Hemophilia Center, clinic one full day per week and weekly clinical conference. 2007-date. From 1992-2007, while running a research lab, I averaged about 10 weeks of inpatient call and had clinics 2-3 days per week. Inpatient Attending Physician, General Pediatric Service, 4-5 weeks per year. 1999-2001. Other clinical effort includes consultation, communications, and peer review associated with protocol patients. Participant, WRAL’s “Doctors on Call” program, NCPS, June 28, 2012. Expert opinion in several litigation cases, 1992-date. Donor, University of North Carolina Shared Leave Program, 360 hours, 1995-date. Pediatric Emergency Room Attending, University of Michigan Medical Center, 1989-1990. Durham East End Clinic, member and provider, 1984-1985. Research/Administrative Service:

20

Judge, UNC Medical School Research Day, January, 2011 Member, UNC Hospital Credentials Committee, 2008-2012. Member, Pediatric Subcommittee, CDC Thrombosis and Hemostasis Centers, 2008-date. Member, CDC Thrombosis and Hemostasis Centers Research and Prevention Network, 2008-date. Participant, Stop the Clot Forum, NATT sponsor, November 22, 2008. Judge, UNC Medical School Research Day, January, 2008. Reviewer of manuscripts: Blood, 1995-1997; J Biol Chem, 1996-1997; Biochimica et Biophysica Acta, 1996; Am J Hum Gen, 1997; Pediatrics, 1998; Cancer Detect Prev, 1999; J Pediatr, 1999-2000; Ann Pharmacother, 2000 and 2002; Human Mutation, 2000; Thromb Haemost, 2000; Clin Lab Haematol, 2001 and 2002; Microbial Pathogenesis, 2002; Int J Cancer, 2004 and 2010; Ann Pharmacother, 2008. Member, Undergraduate Research Subcommittee of the QEP (Quality Enhancement Plan), part of SACS Accreditation for UNC-CH, 2005-2007. Participant, Bleeding and Thrombosing Diseases: 2006 Mayo Clinic Update. Coagulation Workshop and Conference. August 2-4, 2006. Grant reviewer, NCI special emphasis panel (SEP): RFA CA-07-020: Alliance of Glycobiologists for Detection of Cancer and Cancer Risk; Bethesda, November 8-9, 2006. Mentor, Major Challenges in Clinical Medicine: An Overview for Basic Scientists. Supervised 2 post-doctoral fellows, Summer, 2006. Ad Hoc Grant reviewer, at request of NIH CSR, R21 and R15 Structure-Function applications, February 28, 2006. Mentor, RISE Summer Internship Program, supervised one scholar, Summer, 2005. Judge, John K. Koeppe Undergraduate Research Symposium in Biology, April 8, 2005, UNC-CH. Moderator, 6th Annual Celebration of Undergraduate Research, Platform Session V, 2 hours, April 29, 2005, UNC-CH. UNC School of Medicine, Visiting Clinician Program, host for Dr. Gregory Adams, 7 hours, April 27, 2005. Member, Department of Pediatrics Resident Scholarship Oversight Committee: Basic Science

21

Perspective, 2001-2005. Grant reviewer and panel member, NCI, for RFA-CA-04-015, "Strategic Partnering to Evaluate Cancer Signatures" November, 2004. Participant, Quantitative RNA-PCR Workshop, KT Biotechnology, Duke University, 2002. Member, Dean's Standing Committee on Conflict of Interest, UNC-CH School of Medicine, 1997-2001. -Chair of sub-committee monitoring AlphaVax, 2000-2001. Member, Department of Pediatrics Research Committee, 1995-1999. Participant, Antisense Technologies Workshop, Cambridge Healthtech Institute, San Francisco, 1998. Grant review consultant, National Science Foundation, September, 1996, and October, 1997. Co-moderator, Thomas F. Boat Evening of Scholarship, 1994 and 1997. Coordinator, UNC Pediatric Hematology/Oncology Journal Club, 1993-1995. Participant, Analytical Glycobiology Workshop, University of California at San Francisco, 1993. Participant, Carolina Workshop: Transcription, University of North Carolina at Chapel Hill, 1993. Current membership in professional societies and program centers: American Society of Hematology American Society of Pediatric Hematology/Oncology UNC Lineberger Comprehensive Cancer Center Carolina Cardiovascular Biology Center (formerly, The UNC Center for Thrombosis and Hemostasis). Hemophilia of North Carolina (HNC) Member, North Carolina Pediatric Society Member, Floyd Denny Pediatric Society Member, UNC HHT Center of Excellence

22

Reflective Statement: September 2013 Bev Mitchell, a mentor during my junior faculty years at the University of Michigan and here at UNC, was a great role model. She did everything well-- research, teaching, patient care and administration. Versatility became one of my goals. But complex patient care has always been the best part of being an academic physician, and it remains the most important activity for me. Tom Boat, who recruited me for this faculty position 20 years ago, often said that an academic physician should do something different about every 10 years. I finally took his advice in 2007 and closed by research lab, which I ran for about 15 years. Not running a lab has allowed me to contribute more fully to our clinical and teaching missions and to enjoy it more. My previous research focus (1992-2007) involved the study of glycosyltransferase gene expression. Major collaborations included the areas of genomic mapping, linkage analysis, metabolism, infectious disease, organic chemistry, and public health. But when it became clear that clinical applicability for this area of research was limited, it was time to for me to move on. My current interests (2007-date) focus on neutrophil and coagulation disorders. My participation in academics, clinical effort, and other service activities reflect these changes in interests. Many if not most of our patients are entered into clinical trials or registries. Most recently, I have become part of the new HHT Center of Excellence here at UNC. I essentially took on an extra faculty position in 2007, since we had a junior faculty member leave who was seeing hemophilia and thrombosis patients. I have been the primary hematologist for most of those patients since 2007. On April 8, 2005, I wrote a letter to Alan Stiles asking to not be considered for promotion to full professor. In retrospect, that was a good decision, as I have enjoyed developing these new areas of interest. I have also gotten to spend more uninterrupted time with my patients, diversify the types of diseases I treat, and develop new skills in the area of coagulation. This has led me to change my teaching content, methods, and goals. I still have no interest in becoming a full professor. Finally, my family and interests outside of science and medicine have always been important, and I am fortunate to be able to now enjoy this part of life more.

23

ADDENDUM CME, 2007-date (in addition to invited lectures, teaching, papers, grants, and non-supervised education): Activity hr/yr Attendance of Departmental Conferences: Weekly divisional hem-onc case reviews 50 Weekly departmental conferences (about 1/3) 15 Monthly divisional tumor boards 10 Misc. dept. clinical and scientific talks 10 Attendance at Medical, Scientific, and Teaching Meetings: 10 Attendance at UNC & Duke Scientific and Clinical Seminars: Twice monthly, on average 15 Comprehensive Hemophilia Center conferences 25 COG and hemophilia training modules 05 Board reviews 10 Prep of 2 manuscripts (in press) and 2 posters for national meetings 40 CME, 1992-2007 (in addition to invited lectures, teaching, papers, grants, and non-supervised education): Activity hr/yr Attendance of Departmental Conferences: Weekly divisional hematology/oncology case review 50 Weekly departmental grand rounds (about 1/3) 15 Monthly divisional faculty meetings 10 Monthly tumor board meetings 10 Misc. dept. clinical and scientific talks 10 Attendance at Medical, Scientific, and Teaching Meetings: Monthly collaborator meetings 10 Presentation of results at national meetings 10 Attendance of UNC and Duke Scientific Seminars: Monthly, on average 12 Training courses for COG 05

24

ADDENDA: Divisional conferences, teaching schedules, clinical activity reports, meaningful use compliance, and teaching evaluations: available on request.